April 28, 2020 07:20 AM EDT

Gilead fires back in ongoing battle with HHS, suing the government for ‘secretly’ obtaining patents

Jason Mast

Editor

While the world urgently awaits data on their potential coronavirus drug, Gilead continues to duke it out with the government over a life-saving drug for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Gilead fires back in ongoing battle with HHS, suing the government for ‘secretly’ obtaining patents

Jason Mast

Editor

Sign up to read this article for free.

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Halozyme withdraws Evotec acquisition proposal after biotech is 'unwilling to engage'

Are programs with compounded GLP-1s safe for your population?

Gilead fires back in on­go­ing bat­tle with HHS, su­ing the gov­ern­ment for ‘se­cret­ly’ ob­tain­ing patents

Jason Mast

Editor

Sign up to read this article for free.

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Gilead fires back in ongoing battle with HHS, suing the government for ‘secretly’ obtaining patents

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Halozyme withdraws Evotec acquisition proposal after biotech is 'unwilling to engage'

Are programs with compounded GLP-1s safe for your population?